94 related articles for article (PubMed ID: 16387351)
1. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.
Villedieu M; Deslandes E; Duval M; Héron JF; Gauduchon P; Poulain L
Gynecol Oncol; 2006 Jun; 101(3):507-19. PubMed ID: 16387351
[TBL] [Abstract][Full Text] [Related]
2. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
3. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
4. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
[TBL] [Abstract][Full Text] [Related]
5. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
Villedieu M; Briand M; Duval M; Héron JF; Gauduchon P; Poulain L
Gynecol Oncol; 2007 May; 105(2):373-84. PubMed ID: 17276501
[TBL] [Abstract][Full Text] [Related]
6. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
7. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity.
Zhang Y; Shen X
Clin Cancer Res; 2007 May; 13(10):2855-64. PubMed ID: 17504983
[TBL] [Abstract][Full Text] [Related]
9. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
12. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
13. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
Lee S; Yoon S; Kim DH
Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
[TBL] [Abstract][Full Text] [Related]
14. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
15. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2.
Yoon H; Min JK; Lee JW; Kim DG; Hong HJ
Biochem Biophys Res Commun; 2011 Feb; 405(3):333-7. PubMed ID: 21130731
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
19. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance.
Brozovic A; Osmak M
Cancer Lett; 2007 Jun; 251(1):1-16. PubMed ID: 17125914
[TBL] [Abstract][Full Text] [Related]
20. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.
Seidman R; Gitelman I; Sagi O; Horwitz SB; Wolfson M
Exp Cell Res; 2001 Aug; 268(1):84-92. PubMed ID: 11461121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]